The alarm network of the lipid world — signaling molecules made by oxidizing twenty-carbon polyunsaturated fatty acids, chiefly arachidonic acid from membrane phospholipids. Cells never store them; they are synthesized on demand and act locally as autocrine and paracrine mediators of inflammation, fever, pain, and clotting.
The name is Greek for twenty — the carbon count of every precursor; they are a sub-category of the oxylipins.
Three enzyme branches split the family: cyclooxygenases make the prostanoids (prostaglandins, prostacyclin, thromboxanes); 5-lipoxygenase makes leukotrienes and HETEs; CYP enzymes make epoxyeicosatrienoic acids and 20-HETE.
Non-classic members include lipoxins, resolvins, and isoprostanes; resolvins arise from omega-3 EPA, tying the family to omega fatty acid metabolism.
Biosynthesis & Metabolism
Biosynthesis begins when trauma, ischemia, or cytokines activate cytosolic phospholipase A2, freeing arachidonic acid from membrane phospholipids — the start of the arachidonic acid cascade.
Cyclooxygenase converts arachidonate to PGH2, the parent prostanoid, which becomes PGE2, TXA2, or prostacyclin.
5-Lipoxygenase builds LTA4, which splits into LTB4 or the cysteinyl leukotrienes LTC4, LTD4, LTE4 — the asthma mediators released by mast cells.
Cooperation between cells yields lipoxins and resolvins, which resolve inflammation.
Physiological Role
Inflammation: TXA2 is a short-acting vasoconstrictor; PGE2 and LTB4 drive the vasodilation of redness; LTB4 raises the permeability of swelling.
PGE2 sensitizes pain neurons and is a potent pyretic — much of fever and inflammatory pain is prostaglandin-driven.
Hemostasis: platelet TXA2 promotes aggregation while vascular prostacyclin opposes it, a balance mapped in platelet aggregation.
Cysteinyl leukotrienes are potent bronchoconstrictors — dominant mediators of asthmatic airway narrowing.
Interactions
They signal through cell-surface receptors — PTGER1–4 for PGE2, the thromboxane receptor, BLT receptors for LTB4, and CYSLTR1/2 for cysteinyl leukotrienes.
Inhibiting COX-1 and inducible COX-2 is the hallmark of NSAIDs like aspirin — work by Vane in 1971, honored with the 1982 Nobel Prize to Bergström, Samuelsson, and Vane.